A Reappraisal of Hepatitis B Virus Vaccination Strategies Using Cost-Effectiveness Analysis

Abstract

HBV vaccine is most cost-effective when a strategy of screening newborns is combined with routine administration to 10-year-old children. The means to achieve substantial improvements in the health of the public in a cost-effective fashion are now available and should be pursued aggressively.